Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward, CA 94545
United States
510 694 6200
https://www.arcusbio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 577
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO | 1.21M | 無 | 1960 |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President | 889.54k | 無 | 1958 |
| Mr. Robert C. Goeltz II | Principal Financial Officer & CFO | 718.69k | 無 | 1973 |
| Ms. Jennifer A. Jarrett M.B.A. | Chief Operating Officer | 883.69k | 無 | 1971 |
| Dr. Dimitry S.A. Nuyten M.D., Ph.D. | Chief Medical Officer | 823.78k | 無 | 1976 |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board | 無 | 無 | 無 |
| Mr. Alexander Azoy | VP of Finance & Principal Accounting Officer | 無 | 無 | 1976 |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer | 無 | 無 | 1969 |
| Ms. Carolyn C. Tang J.D. | General Counsel & Corporate Secretary | 603.2k | 無 | 1979 |
| Holli Kolkey | Vice President of Corporate Communications | 無 | 無 | 無 |
描述
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
公司管治
截至 2024年5月1日 止，Arcus Biosciences, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：7；董事會：10；股東權利：8；現金賠償：9。
